Published in Cancer Res on December 01, 2006
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A (2007) 3.60
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A (2007) 2.03
HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell (2008) 1.67
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res (2012) 1.51
Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays. PLoS One (2015) 1.40
PP2A regulates HDAC4 nuclear import. Mol Biol Cell (2007) 1.34
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol (2011) 1.34
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood (2008) 1.34
Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin Epigenetics (2011) 1.31
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer (2013) 1.22
The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther (2009) 1.15
Retracted Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem (2010) 1.14
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer (2010) 1.13
Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res (2008) 1.12
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med (2011) 1.07
HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett (2010) 1.06
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol (2011) 1.03
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer (2008) 1.03
DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol (2012) 1.02
Targeting histone deacetylases for the treatment of disease. J Cell Mol Med (2008) 0.94
Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther (2013) 0.92
The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. Front Oncol (2014) 0.92
Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol (2014) 0.90
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer (2014) 0.89
Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro. Oncol Lett (2013) 0.89
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer (2014) 0.89
Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am (2007) 0.86
Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. PLoS One (2013) 0.85
Lung cancer therapeutics that target signaling pathways: an update. Expert Rev Respir Med (2010) 0.82
KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. Biomed Res Int (2014) 0.82
Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res (2014) 0.82
Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks. Genome Integr (2011) 0.82
DNA Repair and Cancer Therapy: Targeting APE1/Ref-1 Using Dietary Agents. J Oncol (2012) 0.81
A role for the histone deacetylase HDAC4 in the life-cycle of HIV-1-based vectors. Virol J (2010) 0.80
Identification of differentially expressed genes between lung adenocarcinoma and lung squamous cell carcinoma by gene expression profiling. Mol Med Rep (2016) 0.80
Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nat Commun (2015) 0.79
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene (2015) 0.79
Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. Radiother Oncol (2013) 0.79
Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer. PLoS Genet (2016) 0.79
Advances in epigenetic glioblastoma therapy. Oncotarget (2017) 0.75
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma. Aging (Albany NY) (2016) 0.75
Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization. Cancer Res Treat (2015) 0.75
Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers. Curr Top Med Chem (2016) 0.75
Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat. Oncotarget (2017) 0.75
Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther (2009) 2.50
SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res (2003) 2.00
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol (2008) 1.98
The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis (2004) 1.87
Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J Natl Cancer Inst (2010) 1.78
Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res (2005) 1.64
Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem (2006) 1.55
Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene (2005) 1.54
Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck (2006) 1.52
Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res (2006) 1.45
XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene (2004) 1.44
Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res (2006) 1.38
Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med (2007) 1.38
Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res (2004) 1.33
Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys (2006) 1.30
A study on adaptive IMRT treatment planning using kV cone-beam CT. Radiother Oncol (2007) 1.30
DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res (2005) 1.30
Noninvasive assessment of cancer response to therapy. Nat Med (2008) 1.23
Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med (2008) 1.22
Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res (2004) 1.22
GSK-3β: A Bifunctional Role in Cell Death Pathways. Int J Cell Biol (2012) 1.21
Impact of inhomogeneity corrections on dose coverage in the treatment of lung cancer using stereotactic body radiation therapy. Med Phys (2007) 1.20
Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res (2002) 1.20
Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res (2010) 1.17
Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med (2004) 1.17
Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer (2005) 1.16
Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in mice. J Clin Invest (2009) 1.13
Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide. J Nucl Med (2012) 1.12
Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging. Cancer (2012) 1.11
SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys (2008) 1.11
Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys (2013) 1.11
Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation. Cancer Res (2008) 1.09
Phantom validation of coregistration of PET and CT for image-guided radiotherapy. Med Phys (2004) 1.07
A new class of molecular targeted radioprotectors: GSK-3beta inhibitors. Int J Radiat Oncol Biol Phys (2010) 1.05
Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med (2007) 1.05
Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline. J Nucl Med (2010) 1.05
In regard to Shah. Int J Radiat Oncol Biol Phys (2013) 1.05
Characterization of superparamagnetic nanoparticle interactions with extracellular matrix in an in vitro system. Ann Biomed Eng (2006) 1.04
Proteolytic surface functionalization enhances in vitro magnetic nanoparticle mobility through extracellular matrix. Nano Lett (2006) 1.04
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther (2006) 1.04
TIP-1 translocation onto the cell plasma membrane is a molecular biomarker of tumor response to ionizing radiation. PLoS One (2010) 1.03
Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3beta in irradiated vascular endothelium. Cancer Res (2006) 1.02
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Int J Radiat Oncol Biol Phys (2006) 1.00
Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J Control Release (2010) 0.99
p53 functions in endothelial cells to prevent radiation-induced myocardial injury in mice. Sci Signal (2012) 0.98
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med (2013) 0.97
Synthesis and structure-activity relationships of 5,6,7-substituted pyrazolopyrimidines: discovery of a novel TSPO PET ligand for cancer imaging. J Med Chem (2013) 0.96
Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging. J Ultrasound Med (2006) 0.96
Radiation-guided drug delivery to mouse models of lung cancer. Clin Cancer Res (2010) 0.95
Sonographic depiction of microvessel perfusion: principles and potential. J Ultrasound Med (2004) 0.95
Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature. FASEB J (2009) 0.94
Correlation of quantified contrast-enhanced sonography with in vivo tumor response. J Ultrasound Med (2010) 0.92
Radiation induces an antitumour immune response to mouse melanoma. Int J Radiat Biol (2009) 0.92
Merkel cell carcinoma. J Natl Compr Canc Netw (2009) 0.90
HIV protease inhibitors enhance the efficacy of irradiation. Cancer Res (2007) 0.90
Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS One (2011) 0.89
Cytosolic phospholipase A2: targeting cancer through the tumor vasculature. Clin Cancer Res (2009) 0.89
Kinomic profiling approach identifies Trk as a novel radiation modulator. Radiother Oncol (2012) 0.89
Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. Bioorg Med Chem (2011) 0.88
Hedgehog signaling in the murine melanoma microenvironment. Angiogenesis (2007) 0.88
Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys (2009) 0.88
Receptor tyrosine kinase inhibitors as anti-angiogenic agents. Curr Opin Investig Drugs (2004) 0.87
A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Mol Imaging Biol (2009) 0.87
Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay. J Control Release (2004) 0.87
Recombinant peptides as biomarkers for tumor response to molecular targeted therapy. Clin Cancer Res (2009) 0.87
STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys (2005) 0.87
Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response. Cancer Res (2003) 0.86
Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis. Anticancer Drugs (2007) 0.85
Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium. Cancer Res (2008) 0.85
The use of tyrosine kinase inhibitors in modifying the response of tumor microvasculature to radiotherapy. Technol Cancer Res Treat (2005) 0.84
Multifunctional FePt nanoparticles for radiation-guided targeting and imaging of cancer. Ann Biomed Eng (2010) 0.84
SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation. Int J Radiat Oncol Biol Phys (2006) 0.84
Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs (2007) 0.83
Radiation-guided gene therapy of cancer. Technol Cancer Res Treat (2006) 0.82
NDRG4, the N-Myc downstream regulated gene, is important for cell survival, tumor invasion and angiogenesis in meningiomas. Integr Biol (Camb) (2012) 0.82
Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. J Natl Compr Canc Netw (2012) 0.82
A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res (2004) 0.81
Determining glioma response to radiation therapy using recombinant peptides. Expert Rev Anticancer Ther (2008) 0.81
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment. Cancer J (2013) 0.81
Deep-inspiration breath-hold kilovoltage cone-beam CT for setup of stereotactic body radiation therapy for lung tumors: initial experience. Lung Cancer (2006) 0.80
Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models. Int J Radiat Oncol Biol Phys (2008) 0.79
PDGFR-beta expression in small cell lung cancer patients. Int J Radiat Oncol Biol Phys (2007) 0.79
Using in vivo biopanning for the development of radiation-guided drug delivery systems. Methods Mol Biol (2009) 0.79
Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int J Radiat Oncol Biol Phys (2004) 0.79
FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys (2003) 0.78